Wilmington Healthcare appoints new director to lead cloud-based healthcare customer intelligence tool
April 1, 2022 | NHS, Promotion, healthcare
Paul Rowe to lead intelligence tool that allows Industry to gain the complete picture of their changing NHS customer base and employ precision planning to access target customers and markets.
Wilmington Healthcare, which provides data, insight and intelligence for pharmaceutical, life sciences and medtech companies, healthcare charities and other NHS suppliers, has appointed Paul Rowe as Solution Director for the company’s Investigator XD product.
With more than 25 years’ experience of sales, marketing and training roles within the pharmaceutical industry, Paul will be responsible for the continuous development of Wilmington Healthcare’s Investigator XD platform as he brings together the company’s unrivalled, unique healthcare data and insight solutions into one cloud-based intelligence tool.
Paul is promoted from the role of Head of Sales at Wilmington Healthcare which he has held for nearly three years. Prior to this Paul has successfully held roles at Daiichi Sankyo and Bayer.
Paul says: “This is an exciting time at Wilmington Healthcare as we integrate our unrivalled data sources and information into one healthcare intelligence tool. We know ‘who’s who’ in the new NHS landscape and what their priorities and focus are better than anyone. And through our powerful insights platform we are able to inspire clients to transform their engagement with NHS customers – at a System, Place and Neighbourhood level – while identifying competitor vulnerability.
“We’re offering the capability to access the most powerful 360 degree view of the System all the way through to the individual customer. By truly integrating System objectives and pressure points, medicines management influences, prescribing decisions and patient outcomes, we are enabling the industry to maximise their market access. This rich data source is complemented by detail of the influential stakeholders, key influencers and opinion leaders across the new landscape in addition to the critical data detailing community demographics and social deprivation to help Industry work with NHS customers to tackle health inequalities and improve population health across care pathways.”
Jonathan Carney, Director of Insights and Key Account Management at Wilmington Healthcare, says: “Seismic shifts in the way the NHS is organised is directly impacting the way it will work with the life science and medtech sectors. This demands a rethink by Industry of the traditional key account management model and NHS customer intelligence tools if they wish to successfully engage, through tailored conversations, in this new environment.
“We are delighted that Paul is leading the next phase of our customer intelligence offering as we work with innovation to ensure that clients have the insight and intelligence to transform their relationships with health and social care partners into credible collaborations.”
For more information about Wilmington Healthcare’s insight and intelligence offer, please visit: https://wilmingtonhealthcare.com/what-we-do/healthcare-insight/
Company Details
Latest Content from Wilmington Healthcare
Considering a portfolio review?
Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...
UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW
Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...
MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...
ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS
With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...
HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...
ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed
Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...
EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES
As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...
UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS
Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...